drugset / Trial / NCT04525144

EGb 761 in the Syndrome of MCI With Concomitant CVD

NCT04525144

RandomizedParallel-groupSingle-blindTreatment

Summary

EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.

Timeline

Start
2020-10-26
Primary completion
2025-12
Completion
2026-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ginkgo Biloba Extract Traditional medicine (herbal / TCM) 120 mg